Asia-Pacific market for anticoccidial drugs is estimated to reach USD 492.64 million by 2023 from USD 397.41 Million in 2018 at a CAGR of 4.39%. Coccidiosis is a parasitic infection of the intestinal tract of animals, which is caused by coccidian protozoa. The disease spreads from one animal to another by any means of contact with infected faeces or consumption of infected tissue which is responsible for devastating mislay in meat production. To overcome this condition, anticoccidial drugs play a vital role in the prevention and treatment of coccidiosis.
Growing demand for meat proteins is increasing the usage of anticoccidial drugs and is acting as major driving force for Asia-Pacific anticoccidial drugs market. Besides, less stringent regulations in these regions and increasing expenditure on companion animals are also assisting in growth of market. Further, the trend of owning companion animals is causative to the growing usage of anticoccidials in developing regions.
The Asia-Pacific anticoccidial drugs market is classified based on various types of animals and by type of drugs used for treatment. The animal segment is sub-categorised into fish, swine, cattle, poultry and companion animals. The companion animal further includes dogs and cats. The livestock industry in the Asian countries has seen steady growth over the past two decades. And on the basis of drug type the market is segmented into antibiotic anticoccidials, Ionophore anticoccidials and chemical derivative anticoccidials. The antibiotic segment has high potential to grow in coming few years. Furthermore, on the basis of geography, the Asia-Pacific Market is analysed under various regions namely, India, China, Japan and South Korea.
Anticoccidial industry is currently facing diverse challenges related to microbial resistance build-up to drugs and increasing government regulations, consequently the major players in the industry are focusing on less regulated markets present in the Asia Pacific regions. Some of the key players operating in the market are Bayer Health care, Zoetis, Merial, Elanco, Virbac, Ceva Santé Animale, Merck Animal Healthcare, Novartis Animal Healthcare, Boehringer Ingelheim Animal Health and Smartvet Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Antibiotic anticoccidials
5.1.2 Ionophore anticoccidials
5.1.3 Chemical derivative anticoccidials
5.2 By Animal Type
5.2.1 Poultry
5.2.2 Swine
5.2.3 Fish
5.2.4 Cattle
5.2.5 Companion Animal
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer Health care
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Zoetis
8.3 Elanco
8.4 Merck Animal Healthcare
8.5 Virbac
8.6 Ceva Santé Animale
8.7 Boehringer Ingelheim Animal Health
8.8 Novartis Animal Healthcare
8.9 Smartvet Inc.
8.10 Market Leader 10
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
